logo
Cancer Survivors Are Skipping the Primary Care Doctor

Cancer Survivors Are Skipping the Primary Care Doctor

Medscape5 hours ago

Fewer than half of cancer survivors visit a primary care clinician during their fifth through seventh years following their diagnosis, according to a new study published in JCO Oncology Practice .
'Primary care providers' engagement with cancer survivors is viewed as really important, not just for detection of a recurrence or a new cancer but to manage chronic diseases that are not cancer-related, like diabetes, and diseases caused or complicated by cancer treatment, like cardiovascular disease,' said Sarah Birken, PhD, associate professor at the Wake Forest University School of Medicine in Winston-Salem, North Carolina, and an author of the study.
Previous research found cancer survivors have improved health outcomes for comorbid conditions when primary care clinicians are involved in their care.
The study included 516 survivors of breast, colorectal, or uterine cancer treated at the Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem. Birken and her colleagues linked cancer registry data to outpatient visits with a physician, nurse practitioner, or physician assistant working in family or internal medicine.
Fewer than half (43%) of patients had one of these visits in years 5, 6, and 7 following their initial diagnosis, defined as 'sustained' engagement.
Those with sustained engagement were 4.6 years older, on average, than those who did not have these visits. The odds of engaging with a primary care clinician rose by 36% for every decade older a person was at the time of cancer diagnosis.
Previous Research
Birken said the findings reinforce those of a 2023 study which found 40% of patients diagnosed with breast cancer reported communicating with primary care clinicians less over time.
Kevin Oeffinger, MD, professor at the Duke University School of Medicine and founding director of the Duke Cancer Institute Center for Onco-Primary Care, Durham, North Carolina, said he was surprised by the findings because of the research showing the importance of primary care in the follow-up of cancer survivors.
'The study highlights the need for better collaboration between primary care providers and oncologists,' Oeffinger, author of an editorial accompanying the journal article, told Medscape Medical News .
A 2005 report by the Institute of Medicine recommended clinicians who coordinate oncology treatment provide patients a survivorship care plan.
Despite 20 years of work since the report, 'there does not appear to be an overall improvement in the quality transition of survivors from the oncology team to the primary care team or evidence that shared care is becoming the norm,' Oeffinger and his coauthors wrote in the editorial.
Going Forward
Birken and her colleagues said their findings should be used to promote engagement of primary care clinicians in long-term care of these patients.
However, she cited some challenges to achieving this goal. Oncologists must have connections with a large number of primary care clinicians for referrals. Primary care clinicians are also often disconnected from patient care during cancer treatments.
Birken said one of the notable findings in the study younger patients were less likely to have visits with primary care clinicians.
'We know that people are being diagnosed with cancer at younger and younger ages, and so an implication of this study could be that we're setting ourselves up for things to worsen with respect to primary care engagement,' Birken said. 'Younger people tend to be less engaged in healthcare; after so many oncology visits following a cancer diagnosis, primary care my feel like yet another unwanted provider visit.'
The study was supported by a grant from the National Cancer Institute's Cancer Center. Oeffinger reported being a consultant for and having stock and other ownership interests in Maia Oncology and receiving research funding from GRAIL.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Brighton High names distinguished grads. Who are Dennis Bowdoin and Arthur Pancioli?
Brighton High names distinguished grads. Who are Dennis Bowdoin and Arthur Pancioli?

Yahoo

time25 minutes ago

  • Yahoo

Brighton High names distinguished grads. Who are Dennis Bowdoin and Arthur Pancioli?

Brighton High School is honoring two graduates for excellence in their respective fields. BHS is inducting Dennis Bowdoin and Dr. Arthur Pancioli to the Brighton Distinguished Alumni Wall of Fame. Brighton Area Schools announced the inductions June 23. Bowdoin and Pancioli will be honored during a ceremony Oct. 16 at BHS. They'll also be part of the school's homecoming parade and celebrated during halftime at the district's homecoming football game Oct. 10. Bowdoin and Pancioli were selected by the Brighton Distinguished Alumni Wall of Fame Committee, entering four years of selections. 'We continue to be amazed as we learn of the incredible stories of Brighton alumni,' BAS Superintendent Matt Outlaw wrote in a release. 'Their success is obvious, but the impact (they're) making on others and the world around them is even more impressive.' Bowdoin graduated from BHS in 1965. He started Movieland Video, growing the business from one store to 360. Bowdoin started the Helicopter Air Specialty Service and was inducted into the Michigan Aviation Hall of Fame in 2024. Bowdoin built the Maple Grove Heliport, managed the Maple Grove and Romeo State Airports, is an FAA Safety Counselor, is a Michigan Aeronautics Consultant, and wrote and ran the helicopter program for Western Michigan University. Bowdoin has also been a planning commissioner in Livingston County, a member of the Conway Township Planning Commission, and Conway Township Constable for 22 years. Pancioli graduated from BHS in 1982. He graduated from the University of Michigan with a bachelor's degree in computer science in 1987, then from U of M Medical School in 1991. Pancioli is the chief clinical officer and senior vice president for the University of Cincinnati Health System and a professor of emergency medicine for the University of Cincinnati College of Medicine. Pancioli was previously chair for the Department of Emergency Medicine in the UC College of Medicine and chief transformation officer for the University of Cincinnati Health System. He specializes in emergency medicine and neurovascular emergencies, and served as a member of the Michigan Air National Guard from 1989-1993 as a flight surgeon before earning the rank of captain. He's also published several peer-reviewed publications. Other members of the Brighton Distinguished Alumni Wall of Fame include Drew Henson (Class of 1998), Dave LewAllen (1975), Kate Lawrence (1976), Col. Dr. Karin Flood (1988), Bruce Ritter (1971), Kari Seitz (1988) and Charles Brady (1941). 'It's such a pleasure to tell the stories of these outstanding alumni every year,' Outlaw said. 'Each story offers us a chance to celebrate as a community but also provides wonderful examples for our students of what is possible with hard work and dedication.' — Contact reporter Evan Sasiela at esasiela@ Follow him on X @SalsaEvan. This article originally appeared on Livingston Daily: Who are BHS grads Dennis Bowdoin and Arthur Pancioli?

Thermo Fisher, Ethris Partner to Offer Integrated mRNA Solutions for Biopharma
Thermo Fisher, Ethris Partner to Offer Integrated mRNA Solutions for Biopharma

Yahoo

timean hour ago

  • Yahoo

Thermo Fisher, Ethris Partner to Offer Integrated mRNA Solutions for Biopharma

Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the most active stocks to buy according to analysts. On June 13, Ethris announced a collaboration with Thermo Fisher Scientific. The partnership aims to provide a fully integrated messenger ribonucleic acid (mRNA) solution to biopharmaceutical developers globally. The core objective of the collaboration is to accelerate the progression of candidate mRNA medicines from the research phase to clinical proof-of-concept. The partnership will use Ethris' advanced mRNA technology platforms, including its proprietary Stabilized Non-Immunogenic mRNA (SNIM RNA), minimal UTR, and mRNA manufacturing technologies. These will be combined with Thermo Fisher Scientific's industry-leading end-to-end good manufacturing practice/GMP-compliant manufacturing capabilities. A workstation in a research lab stocked with laboratory products and services. Ethris' platform technologies have already shown promising results. Specifically, the company's lead candidate, ETH47, has shown favorable outcomes in Phase I trials. ETH47 is designed for local administration via nasal spray to target asthma exacerbations and showed dose-dependent and localized production of the encoded protein (interferon lambda) at the site of administration, with no systemic bioavailability. The study confirmed the functional activity of the expressed protein by activating downstream signaling. The non-immunogenic nature of SNIM RNAs allows for repeated administration, which leads to sustained production of therapeutically active proteins within the human body. The technology is versatile, suitable for multiple routes of administration, and can be used to replace or augment missing or non-functional proteins, introduce new proteins to modulate disease, or develop vaccines. Thermo Fisher Scientific Inc. (NYSE:TMO) provides life sciences solutions, analytical instruments, specialty diagnostics, laboratory products, and biopharma services internationally. Ethris is a clinical-stage biotechnology company that has paved a new path from genes to therapeutic proteins. While we acknowledge the potential of TMO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio

Novo Nordisk Fast-Tracks Amycretin to Phase 3 for Obesity Treatment
Novo Nordisk Fast-Tracks Amycretin to Phase 3 for Obesity Treatment

Yahoo

timean hour ago

  • Yahoo

Novo Nordisk Fast-Tracks Amycretin to Phase 3 for Obesity Treatment

Novo Nordisk (NYSE:NVO) is one of the most active stocks to buy according to analysts. On June 20, Novo Nordisk announced that its investigational obesity treatment, amycretin, will advance directly to Phase 3 clinical development. The decision is based on promising results from two early-phase clinical trials: one for a once-weekly subcutaneous formulation and another for a once-daily oral formulation. These were published in The Lancet. Both formulations will progress to Phase 3 for weight management, which is a move supported by completed clinical studies and positive feedback from regulatory authorities. The executive vice president for Development at Novo Nordisk, Martin Holst Lange, expressed satisfaction with the results and regulatory feedback and highlighted the company's commitment to addressing obesity and expanding treatment options. An elderly couple receiving insulin from a pharmacist, representing healthcare company's successful pharmaceutical products. Amycretin is a unimolecular, long-acting GLP-1 and amylin receptor agonist, which is designed to target appetite regulation. It is being developed for adults with overweight or obesity, and also as a potential treatment for adults with type 2 diabetes. While Amycretin is not yet approved in the US for weight loss, these positive early-phase results strongly support its continued investigation in larger and longer-term Phase 3 trials to further assess its efficacy and safety. Novo Nordisk (NYSE:NVO) engages in the research & development, manufacture, and distribution of pharmaceutical products internationally. It has 2 segments: Diabetes & Obesity Care and Rare Disease. While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store